Rana R. McKay, MD, discusses KEYNOTE-564 and the future of adjuvant immunotherapy in renal cell carcinoma.
Rana R. McKay, MD, a medical oncologist and associate professor of Medicine at the University of California San Diego Health, discusses KEYNOTE-564 (NCT03142334) and how it can lead us in the right direction for the future of adjuvant immunotherapy in renal cell carcinoma (RCC).
While adjuvant immunotherapy in patients with RCC has demonstrated efficacy and improved overall survival, there are only a scarcity of agents which can be used in this setting.
The introduction of checkpoint inhibitors for patients with advanced RCC made it so testing could occur in the adjuvant setting. This led to the creation of KEYNOTE-564, the first adjuvant immunotherapy trial to report on RCC.
Based on the study’s results, pembrolizumab (Keytruda) was approved by the FDA for the use of RCC with an intermediate-high or high-risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions for adjuvant use in November 2021. The phase 3 trial was overall positive as it met its primary end point of improved disease-free survival, according to McKay.
Transcription:
0:08 | I think this trial is a landmark study that catapults us into a new era in renal cell carcinoma of testing the utility of adjuvant checkpoint inhibitors for patients with advanced disease, or localized disease that's high risk of recurring. There's going to be a series of other trials that are going to report out over the next several years that I think are going to further inform the field. As we get additional follow-up data from KEYNOTE-564, we will begin to understand the implications of the therapy with regards to overall survival.
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 8th 2024During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Read More